Alcohol-related liver disease and nalmefene

Not Applicable

Recruiting

• Conditions: Alcohol related liver disease; harm reduction, drinking marker

• Registration Number: JPRN-jRCT1031220022
• Lead Sponsor: Ikejima Kenichi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-04-14
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1) Outpatients aged 20 to 80
2) Patients who have a heavy drinking habit exceeding 60 g / day for men and 40 g / day for women in terms of pure alcohol and meet the diagnostic criteria of the ICD-10 diagnostic guidelines for alcohol dependence syndrome
3) Patients who did not abstain from alcohol after the pre-observation period (4 to 12 weeks) and had a serum GGT level of 100 IU / L or higher
4) Patients who have written consent to participate in this study

Exclusion Criteria

1) Patients treated for viral hepatitis, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis or metabolic liver disease)
2) Patients with decompensated cirrhosis (Child-Pugh grade C)
3) Patients who are taking contraindications of nalmefene such as opioids
4) Patients with advanced or malignant tumor requiring treatment
5) Pregnant or suspected pregnant, lactating patients
6) Patients judged to be ineligible by a doctor

Study & Design

• Study Type: Interventional
• Study Design: Not specified